Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Cancer

Volumn 122, Issue 3, 2016, Pages 367-377

  Harding, James J ^a,b   El Dika, Imane ^c   Abou Alfa, Ghassan K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

checkpoint inhibitors; hepatocellular carcinoma; immune evasion; immunotherapy

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; GALUNISERTIB; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 7 RECEPTOR; LIRILUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NIVOLUMAB; ONCOLYTIC VIRUS; SORAFENIB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; LY-2157299; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ADVANCED CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROCEDURES; T LYMPHOCYTE; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; CYTOKINES; HEPATITIS, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERONS; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRAZOLES; QUINOLINES; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84948783235     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29769     Document Type: Review

References (121)

1. Postow MA, Harding J, Wolchok JD,. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 2012; 18: 153-159.
2. Harding JJ, Abou-Alfa GK,. Treating advanced hepatocellular carcinoma: how to get out of first gear. Cancer. 2014; 120: 3122-3130.
3. Jenne CN, Kubes P,. Immune surveillance by the liver. Nat Immunol. 2013; 14: 996-1006.
4. Thomson AW, Knolle PA,. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010; 10: 753-766.
5. Limmer A, Ohl J, Kurts C, et al., Efficient presentation of exogenous antigen by liver endothelial cells to CD8 + T cells results in antigen-specific T-cell tolerance. Nat Med. 2000; 6: 1348-1354.
6. Carambia A, Frenzel C, Bruns OT, et al., Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J Hepatol. 2013; 58: 112-118.
7. Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA,. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8 + T cell tolerance. Hepatology. 2008; 47: 296-305.
8. Knolle PA, Germann T, Treichel U, et al., Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol. 1999; 162: 1401-1407.
9. Knolle PA, Uhrig A, Hegenbarth S, et al., IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin Exp Immunol. 1998; 114: 427-433.
10. Schildberg FA, Hegenbarth SI, Schumak B, Scholz K, Limmer A, Knolle PA,. Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells. Eur J Immunol. 2008; 38: 957-967.
11. Heymann F, Peusquens J, Ludwig-Portugall I, et al., Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015; 62: 279-291.
12. You Q, Cheng L, Kedl RM, Ju C,. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology. 2008; 48: 978-990.
13. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP,. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004; 172: 1009-1017.
14. Lever M, Maini PK, van der Merwe PA, Dushek O,. Phenotypic models of T cell activation. Nat Rev Immunol. 2014; 14: 619-629.
15. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
16. Postow MA, Callahan MK, Wolchok JD,. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33: 1974-1982.
17. Curtsinger JM, Schmidt CS, Mondino A, et al., Inflammatory cytokines provide a third signal for activation of naive CD4 + and CD8 + T cells. J Immunol. 1999; 162: 3256-3262.
18. Jiang Y, Li Y, Zhu B,. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6: e1792.
19. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS,. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology. 2009; 50: 1625-1637.
20. Reignat S, Webster GJ, Brown D, et al., Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002; 195: 1089-1101.
21. Fisicaro P, Valdatta C, Massari M, et al., Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010; 138: 682-693.e1-e4.
22. Bengsch B, Martin B, Thimme R,. Restoration of HBV-specific CD8 + T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol. 2014; 61: 1212-1219.
23. Owusu Sekyere S, Suneetha PV, Kraft AR, et al., A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J Hepatol. 2015; 62: 31-40.
24. Tzeng HT, Tsai HF, Liao HJ, et al., PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One. 2012; 7: e39179.
25. Schurich A, Khanna P, Lopes AR, et al., Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011; 53: 1494-1503.
26. Nakamoto N, Kaplan DE, Coleclough J, et al., Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology. 2008; 134: 1927-1937, 1937.e1-e2.
27. Nebbia G, Peppa D, Schurich A, et al., Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One. 2012; 7: e47648.
28. Nakamoto N, Cho H, Shaked A, et al., Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009; 5: e1000313.
29. Budhu A, Forgues M, Ye QH, et al., Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10: 99-111.
30. Li M, Sun R, Xu L, et al., Kupffer cells support hepatitis B virus-mediated CD8 + T cell exhaustion via hepatitis B core antigen-TLR2 interactions in mice. J Immunol. 2015; 195: 3100-3109.
31. Xu D, Fu J, Jin L, et al., Circulating and liver resident CD4+CD25 + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol. 2006; 177: 739-747.
32. Alatrakchi N, Koziel M,. Regulatory T cells and viral liver disease. J Viral Hepat. 2009; 16: 223-229.
33. Zhang HH, Mei MH, Fei R, et al., Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010; 17 (suppl 1): 34-43.
34. Cabrera R, Tu Z, Xu Y, et al., An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004; 40: 1062-1071.
35. Martinet J, Dufeu-Duchesne T, Bruder Costa J, et al., Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology. 2012; 143: 1586-1596.e8.
36. Tatsumi T, Takehara T, Katayama K, et al., Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 1997; 25: 1108-1114.
37. Fujiwara K, Higashi T, Nouso K, et al., Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2004; 19: 1121-1127.
38. Matsui M, Machida S, Itani-Yohda T, Akatsuka T,. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol. 2002; 17: 897-907.
39. Han Y, Chen Z, Yang Y, et al., Human CD14 + CTLA-4 + regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. 2014; 59: 567-579.
40. Suresh KG, Lugade AA, Miller A, Iyer R, Thanavala Y,. Higher frequencies of GARP + CTLA-4 + Foxp3 + T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T cell functionality. Cancer Res. 2013; 73: 2435-2444.
41. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, et al., Activated tumor-infiltrating CD4 + regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology. 2013; 57: 183-194.
42. Hoechst B, Ormandy LA, Ballmaier M, et al., A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+) Foxp3(+) T cells. Gastroenterology. 2008; 135: 234-243.
43. Kuang DM, Zhao Q, Peng C, et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206: 1327-1337.
44. Cariani E, Pilli M, Zerbini A, et al., Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One. 2012; 7: e32493.
45. Xia Y, Chen R, Ye SL, Sun R, Chen J, Zhao Y,. Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clin Exp Metastasis. 2011; 28: 661-674.
46. Gao Q, Qiu SJ, Fan J, et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25: 2586-2593.
47. Zeng Z, Shi F, Zhou L, et al., Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011; 6: e23621.
48. Wu K, Kryczek I, Chen L, Zou W, Welling TH,. Kupffer cell suppression of CD8 + T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009; 69: 8067-8075.
49. Gao Q, Wang XY, Qiu SJ, et al., Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15: 971-979.
50. Wang BJ, Bao JJ, Wang JZ, et al., Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011; 17: 3322-3329.
51. Faivre SJ, Santoro A, Kelley RK, et al., A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol. 2014; 32 (suppl 3): Abstract LBA173.
52. Shen Y, Wei Y, Wang Z, et al., TGF-beta regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem. 2015; 35: 1623-1632.
53. Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI,. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8 + T cell deletion and viral persistence in vivo. Immunity. 2009; 31: 145-157.
54. Bhardwaj N, Li M, Price T, Maddern GJ,. Spontaneous regression of a biopsy confirmed hepatocellular carcinoma. BMJ Case Rep. 2014. doi: 10.1136/bcr-2014-204897.
55. Ayaru L, Pereira SP, Alisa A, et al., Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007; 178: 1914-1922.
56. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH,. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol. 2006; 177: 712-721.
57. Xu Y, Li H, Gao RL, Adeyemo O, Itkin M, Kaplan DE,. Expansion of interferon-gamma-producing multifunctional CD4 + T-cells and dysfunctional CD8 + T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol. 2011; 139: 302-313.
58. Korangy F, Ormandy LA, Bleck JS, et al., Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 2004; 10: 4332-4341.
59. Zhang XM, Zhang YF, Huang Y, et al., The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. Oncol Rep. 2008; 20: 245-252.
60. Sera T, Hiasa Y, Mashiba T, et al., Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer. 2008; 44: 600-608.
61. Mizukoshi E, Nakamoto Y, Marukawa Y, et al., Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology. 2006; 43: 1284-1294.
62. Adotevi O, Mollier K, Neuveut C, et al., Immunogenic HLA-B∗0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res. 2006; 12: 3158-3167.
63. Zerbini A, Pilli M, Soliani P, et al., Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol. 2004; 40: 102-109.
64. Flecken T, Schmidt N, Hild S, et al., Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma. Hepatology. 2014; 59: 1415-1426.
65. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF,. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005; 28: 496-504.
66. Palmer DH, Midgley RS, Mirza N, et al., A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009; 49: 124-132.
67. Greten TF, Forner A, Korangy F, et al., A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010; 10: 209.
68. Sawada Y, Yoshikawa T, Nobuoka D, et al., Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012; 18: 3686-3696.
69. Tada F, Abe M, Hirooka M, et al., Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 2012; 41: 1601-1609.
70. Abei M, Okumura T, Fukuda K, et al., A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol. 2013; 8: 239.
71. Butterfield LH, Economou JS, Gamblin TC, Geller DA,. Alpha fetoprotein DNA prime and adenovirus boost immunization of 2 hepatocellular cancer patients. J Transl Med. 2014; 12: 86.
72. Butterfield LH, Ribas A, Meng WS, et al., T-cell responses to HLA-A∗0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003; 9 (16 pt 1): 5902-5908.
73. Carreno BM, Magrini V, Becker-Hapak M, et al., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348: 803-808.
74. Lai CL, Wu PC, Lok AS, et al., Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer. 1989; 60: 928-933.
75. Colleoni M, Buzzoni R, Bajetta E, et al., A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993; 72: 3196-3201.
76. Falkson G, Lipsitz S, Borden E, Simson I, Haller D,. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol. 1995; 18: 287-292.
77. Llovet JM, Sala M, Castells L, et al., Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 31: 54-58.
78. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H,. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002; 89: 418-422.
79. Lin SM, Lin CJ, Hsu CW, et al., Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004; 100: 376-382.
80. Sun HC, Tang ZY, Wang L, et al., Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132: 458-465.
81. Mazzaferro V, Romito R, Schiavo M, et al., Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44: 1543-1554.
82. Lo CM, Liu CL, Chan SC, et al., A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007; 245: 831-842.
83. Bruix J, Poynard T, Colombo M, et al., Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011; 140: 1990-1999.
84. Chen LT, Chen MF, Li LA, et al., Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012; 255: 8-17.
85. Heo J, Reid T, Ruo L, et al., Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013; 19: 329-336.
86. Park BH, Hwang T, Liu TC, et al., Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008; 9: 533-542.
87. Burke JM, Breitbach C, Patt RH, et al., Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE) [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract TPS4152.
88. Sangro B, Gomez-Martin C, de la Mata M, et al., A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59: 81-88.
89. Duffy A, Makarova-Rusher O, Kerkar S, et al., A pilot study of tremelimumab-a monoclonal antibody against CTLA-4-in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol. 2015; 33 (suppl). Abstract 4081.
90. El-Khoueiry A, Melero I, Crocenzi T, et al., Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040 [abstract]. J Clin Oncol. 2015; 33 (suppl). Abstract LBA101.
91. Segal N, Hamid O, Hwu W, et al., A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data. Ann Oncol. 2014; 25: iv361-iv372.
92. Minter S, Willner I, Shirai K,. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol. 2013; 31: e307-e308.
93. Sharma A, Thompson JA, Repaka A, Mehnert JM,. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol. 2013; 31: e370-e372.
94. Ravi S, Spencer K, Ruisi M, et al., Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer. 2014; 2: 33.
95. Gardiner D, Lalezari J, Lawitz E, et al., A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One. 2013; 8: e63818.
96. Barathan M, Gopal K, Mohamed R, et al., Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis. 2015; 20: 466-480.
97. Li H, Wu K, Tao K, et al., Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012; 56: 1342-1351.
98. Cariani E, Missale G,. KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma. Oncoimmunology. 2013; 2: e26622.
99. Gauttier V, Judor JP, Le Guen V, Cany J, Ferry N, Conchon S,. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer. 2014; 135: 2857-2867.
100. Morales-Kastresana A, Sanmamed MF, Rodriguez I, et al., Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013; 19: 6151-6162.
101. Larkin J, Chiarion-Sileni V, Gonzalez R, et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23-34.
102. Ribas A, Wolchok JD,. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013; 25: 291-296.
103. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G,. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013; 39: 74-88.
104. Cabrera R, Ararat M, Xu Y, et al., Immune modulation of effector CD4 + and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2013; 62: 737-746.
105. Chen ML, Yan BS, Lu WC, et al., Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer. 2014; 134: 319-331.
106. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D,. MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther. 2009; 8: 433-440.
107. Zhao W, Gu YH, Song R, Qu BQ, Xu Q,. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 2008; 22: 1226-1233.
108. Alfaro C, Suarez N, Gonzalez A, et al., Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100: 1111-1119.
109. Hipp MM, Hilf N, Walter S, et al., Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008; 111: 5610-5620.
110. Sprinzl MF, Reisinger F, Puschnik A, et al., Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology. 2013; 57: 2358-2368.
111. Chen Y, Ramjiawan RR, Reiberger T, et al., CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015; 61: 1591-1602.
112. Labiano S, Palazon A, Melero I,. Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol. 2015; 42: 378-386.
113. Palazon A, Martinez-Forero I, Teijeira A, et al., The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov. 2012; 2: 608-623.
114. Noman MZ, Desantis G, Janji B, et al., PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211: 781-790.
115. Ikei S, Ogawa M, Beppu T, et al., Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma. Cytokine. 1992; 4: 581-584.
116. Pinato DJ, Sharma R,. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res. 2012; 160: 146-152.
117. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Signatures of mutational processes in human cancer. Nature. 2013; 500: 415-421.
118. Rizvi NA, Hellmann MD, Snyder A, et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-128.
119. Le DT, Uram JN, Wang H, et al., PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509-2520.
120. Schulze K, Imbeaud S, Letouze E, et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47: 505-511.
121. Chiou VL, Burotto M,. Pseudoprogression and immune-related response in solid tumors [published online ahead of print August 10, 2015]. J Clin Oncol.